Molecular mechanisms of human IRE1 activation through dimerization and ligand binding

by Joshi, Amar, Newbatt, Yvette, McAndrew, P. Craig, Stubbs, Mark, Burke, Rosemary, Richards, Mark W., Bhatia, Chitra, Caldwell, John J., McHardy, Tatiana, Collins, Ian, Bayliss, Richard
Published 2015

Discovery of 3-Alkoxyamino-5-(pyridin-2-ylamino)pyrazine-2-carbonitriles as Selective, Orally Bioavailable CHK1 Inhibitors

by Lainchbury, Michael, Matthews, Thomas P., McHardy, Tatiana, Boxall, Kathy J., Walton, Michael I., Eve, Paul D., Hayes, Angela, Valenti, Melanie R., de Haven Brandon, Alexis K., Box, Gary, Aherne, G. Wynne, Reader, John C., Raynaud, Florence I., Eccles, Suzanne A., Garrett, Michelle D., Collins, Ian
Published 2012

The clinical development candidate CCT245737 is an orally active CHK1 inhibitor with preclinical activity in RAS mutant NSCLC and Eμ-MYC driven B-cell lymphoma

by Walton, Mike I., Eve, Paul D., Hayes, Angela, Henley, Alan T., Valenti, Melanie R., De Haven Brandon, Alexis K., Box, Gary, Boxall, Kathy J., Tall, Matthew, Swales, Karen, Matthews, Thomas P., McHardy, Tatiana, Lainchbury, Michael, Osborne, James, Hunter, Jill E., Perkins, Neil D., Aherne, G. Wynne, Reader, John C., Raynaud, Florence I., Eccles, Suzanne A., Collins, Ian, Garrett, Michelle D.
Published 2015